Navigation Links
EJK Duisburg Becomes One of the Most Active SynCardia Certified Centers in Europe
Date:8/15/2012

TUCSON, Ariz., Aug. 15, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that Evangelischen und Johanniter Klinikum Niederrhein (EJK Duisburg) in Germany has become one of the most active SynCardia Certified Centers in Europe.

(Photo: http://photos.prnewswire.com/prnh/20120815/LA57714)

"End-stage biventricular heart failure is a lethal disease," said Prof. Dr. med. Gero Tenderich. "Previously, treatment for this condition was limited to heart transplantation. However, this therapy is currently being challenged by an increasing shortage of suitable donor hearts and an aging society. The SynCardia temporary Total Artificial Heart achieves excellent results as a bridge to transplantation for survival, end-organ recovery and quality of life. As a highly specialized, high-volume transplant center, we consider implantation of the Total Artificial Heart for both chronic and acute cases."

On March 2, 53-year-old Ralf Becker became the first Total Artificial Heart patient at EJK Duisburg to be discharged from the hospital using the Freedom® portable driver. Weighing approximately 6 kg, the Freedom driver is the world's first wearable power supply for the SynCardia Total Artificial Heart.

"I can climb the stairs to our apartment on the third floor with almost no problem," said Mr. Becker. "Twice daily I ride for half an hour on the bicycle, and twice a week I do physical therapy. When your family stands behind you, each new day is a gift."

Mr. Becker was implanted with the Total Artificial Heart on Jan. 20, just 10 days after suffering a severe heart attack. On July 1, he and his wife Silvia, who have three children, celebrated their 24th wedding anniversary.

On June 9, 63-year-old Total Artificial Heart patient Friedhelm Rosheim was discharged from EJK Duisburg to wait for a matching donor heart at home using the Freedom driver. Since his discharge, Mr. Rosheim says he has been able to jog, climb stairs, go cycling and go out to dinner with his family.

"Mr. Rosheim and Mr. Becker have experienced an exciting improvement in quality of life," said Prof. Dr. med. Tenderich. "Walking, riding a bicycle and going out to eat with family and friends are all possible due to the small size and simple handling of the Freedom portable driver. Their trust in God and medicine keeps them going."

Worldwide, the Freedom driver has supported more than 90 patients accounting for more than 34 patient years of support. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

SynCardia Wins Two Gold Stevies® at 2012 American Business Awards

On June 18, 2012, SynCardia was honored with two Gold Stevie® Awards at the 10th Annual American Business Awards. SynCardia won "Company of the Year – Health Products and Services" and "Most Innovative Company of the Year – up to 100 Employees." See the full list of SynCardia Awards & Recognition, which includes accolades from Forbes, Fast Company and more.


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Austin Recovery Becomes Learning Environment for Texas A&M Health Science Center Medical Students
2. Med Centro Becomes First SuccessEHS Client to Go Live in Puerto Rico
3. New Molecular Assay Allows Healthcare Facilities to Simplify Active Surveillance Testing for Deadly Superbug
4. United Seating & Mobility Completes Acquisition of Active American Mobilitys Rehab Division
5. United Seating & Mobility Completes Acquisition of Active American Mobility
6. FDA clears Accu-Chek Combo system - Roches new interactive insulin pump system for people with diabetes
7. AUA Foundation Launches Campaign to Address Stigma of Overactive Bladder
8. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
9. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
10. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
11. Warm Weather Means Active Children May Be Prone To More Injuries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... BOTHELL, Wash. , May 4, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... media ("BioLife" or the "Company"), today announced that ... released after market close on Thursday, May 11, 2017, ... and live webcast at 1:30 p.m. PT that afternoon. ...
(Date:5/3/2017)... May 3, 2017  Kalorama Information notes that ... percent next year and this is projected to ... stem cell (HSCT) or bone marrow transplants require ... are well-suited for this task. This according to ... Kalorama Information. The various PCR-based methodologies, Sanger sequencing ...
(Date:5/3/2017)... May 3, 2017  West Pharmaceutical Services, Inc. ... for injectable drug administration, announced today that ... Technical Services, and Diane Paskiet , Director, ... presentations focused on West,s expertise in the areas ... well as providing commentary on updated industry guidance. ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... 2017 , ... “Homeostasis: The Journey of a Manic-Depressive” tells the story in ... Rodriguez takes readers on a rollercoaster ride that includes a midnight trek to the ... a dark place where Donald considers suicide. Readers learn how Donald finally achieves ...
(Date:5/22/2017)... TX (PRWEB) , ... May 22, 2017 , ... Faithfully ... with a body squatted, stretched, jumped, toned and shaped through fitness programs. It carries ... is, of course, finished off with an irresistible, radiant smile. CDA has ...
(Date:5/22/2017)... ... May 22, 2017 , ... OSF Ventures, ... investing in InsightRX, an early stage company in San Francisco that has developed ... Greatpoint Ventures Innovation Fund acted as the lead investor in the ...
(Date:5/21/2017)... ... May 19, 2017 , ... HealthSmart, the largest independent benefits ... Vertino as Chief Information Officer (CIO). He will be joining HealthSmart at the ... business performance. He defines strategic roadmaps by reimagining business processes—bridging the gap between ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pixel Film Studios presents ... use in Final Cut Pro X. The business-oriented elements and dignified animations are ... ProParagraph Corporate will deliver a professional and distinguished look to any multi-line text ...
Breaking Medicine News(10 mins):